391 related articles for article (PubMed ID: 14615373)
1. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
[TBL] [Abstract][Full Text] [Related]
2. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
3. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
DiJoseph JF; Goad ME; Dougher MM; Boghaert ER; Kunz A; Hamann PR; Damle NK
Clin Cancer Res; 2004 Dec; 10(24):8620-9. PubMed ID: 15623646
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
Dijoseph JF; Dougher MM; Armellino DC; Evans DY; Damle NK
Leukemia; 2007 Nov; 21(11):2240-5. PubMed ID: 17657218
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
[TBL] [Abstract][Full Text] [Related]
6. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
Damle NK; Frost P
Curr Opin Pharmacol; 2003 Aug; 3(4):386-90. PubMed ID: 12901947
[TBL] [Abstract][Full Text] [Related]
7. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
[TBL] [Abstract][Full Text] [Related]
8. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
Damle NK
Expert Opin Biol Ther; 2004 Sep; 4(9):1445-52. PubMed ID: 15335312
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
10. Epratuzumab: targeting B-cell malignancies through CD22.
Coleman M; Goldenberg DM; Siegel AB; Ketas JC; Ashe M; Fiore JM; Leonard JP
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
[TBL] [Abstract][Full Text] [Related]
11. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
de Vries JF; Zwaan CM; De Bie M; Voerman JS; den Boer ML; van Dongen JJ; van der Velden VH
Leukemia; 2012 Feb; 26(2):255-64. PubMed ID: 21869836
[TBL] [Abstract][Full Text] [Related]
12. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R
Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
14. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
16. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
Takeshita A; Yamakage N; Shinjo K; Ono T; Hirano I; Nakamura S; Shigeno K; Tobita T; Maekawa M; Kiyoi H; Naoe T; Ohnishi K; Sugimoto Y; Ohno R
Leukemia; 2009 Jul; 23(7):1329-36. PubMed ID: 19369961
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
18. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP.
DiJoseph JF; Dougher MM; Evans DY; Zhou BB; Damle NK
Cancer Chemother Pharmacol; 2011 Apr; 67(4):741-9. PubMed ID: 20521053
[TBL] [Abstract][Full Text] [Related]
19. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Ogura M; Hatake K; Ando K; Tobinai K; Tokushige K; Ono C; Ishibashi T; Vandendries E
Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
